---
title: "Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293917050.md"
description: "Kura Oncology reported up to 50% response rates for darlifarnib-cabozantinib in Phase 1a kidney cancer trials. The combination showed durable tumor shrinkage and manageable safety in pretreated patients. A randomized Phase 1b study is enrolling in the US and EU to determine the recommended Phase 3 dose, with a registrational study targeted for 2028."
datetime: "2026-07-27T10:32:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293917050.md)
  - [en](https://longbridge.com/en/news/293917050.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293917050.md)
---

# Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial

-   Kura Oncology disclosed updated Phase 1a results already presented at KCRS 2026 for darlifarnib with cabozantinib in advanced clear cell renal cell carcinoma. \* The combination produced durable tumor shrinkage in a pretreated, cabozantinib-naïve population, supporting continued development in later-line settings. \* Safety looked manageable, broadly matching known profiles of the two drugs, with side effects handled mainly through dosing adjustments. \* A randomized Phase 1b study is enrolling in the U.S. and EU, testing the combination versus cabozantinib alone to set a recommended Phase 3 dose. \* Kura targets a registrational study in 2028, positioning the regimen as a potential option following immunotherapy-based treatment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270632PRIMZONEFULLFEED9778158) on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [KURA.US](https://longbridge.com/en/quote/KURA.US.md)

## Related News & Research

- [Kura Oncology posts investor presentation on darlifarnib plus cabozantinib clinical update in renal cell carcinoma](https://longbridge.com/en/news/293940059.md)
- [Kura Oncology updates CEO Troy Wilson severance terms in revised employment agreement](https://longbridge.com/en/news/294265229.md)
- [Arcus Biosciences (RCUS) Expands Kidney Cancer Collaboration, Is The Stock Still Undervalued?](https://longbridge.com/en/news/294713542.md)
- [FDA approves Novartis Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer](https://longbridge.com/en/news/294553335.md)
- [Cerenome Launches as an Integrated CNS Oncology Company | PSTV Stock News](https://longbridge.com/en/news/294514925.md)